Elevated LDL or triglycerides; statin therapy stratified by ACC/AHA risk groups.
Also known as: dyslipidemia, hypercholesterolemia, high cholesterol, LDL, statin
Overview
Elevated serum lipid levels — total cholesterol, LDL, or triglycerides — or low HDL. Primary modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Severe hypertriglyceridemia (TG ≥500 mg/dL) carries a distinct risk of acute pancreatitis.
Try two board-style Hyperlipidemia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1CardiovascularEasy
A 60-year-old man started rosuvastatin 40 mg daily. At 3 months he reports bilateral thigh and calf muscle aches with weakness. Creatine kinase (CK) is 4,800 U/L (reference <200 U/L). Which of the following is the most appropriate next step?
ADiscontinue rosuvastatin promptly
BContinue rosuvastatin and recheck CK
CAdd coenzyme Q10 supplementation
DReduce rosuvastatin to 10 mg daily
ESwitch immediately to pravastatin
Reveal answer & full explanation
Correct answer: A — Discontinue rosuvastatin promptly
ADiscontinue rosuvastatin promptly✓
BContinue rosuvastatin and recheck CK
CAdd coenzyme Q10 supplementation
DReduce rosuvastatin to 10 mg daily
ESwitch immediately to pravastatin
Why Discontinue rosuvastatin promptly is correct
Statin-associated myopathy with a CK greater than 10 times the upper limit of normal (here ~24×) plus muscle symptoms mandates stopping the statin immediately to prevent progression to rhabdomyolysis, myoglobinuria, and acute kidney injury
After stopping, hydrate and trend CK and renal function until CK normalizes; check TSH because hypothyroidism predisposes to statin myopathy
A lower-myopathy-risk statin (e.g., pravastatin) may be cautiously reintroduced once CK has normalized
Why the others are wrong
Reduce rosuvastatin to 10 mg daily — dose reduction is a reasonable strategy for tolerable myalgias with a normal or minimally elevated CK, but CK >10× ULN with weakness requires stopping the drug entirely and trending CK and renal function (right-strategy-wrong-severity)
Add coenzyme Q10 supplementation — CoQ10 is not an evidence-based treatment for statin myopathy and does not remove the offending drug (buzzword-matching myalgia to a supplement)
Switch immediately to pravastatin — any rechallenge must wait until CK normalizes and renal function is confirmed stable; switching now perpetuates exposure during active myopathy (right-idea-wrong-timing)
Continue rosuvastatin and recheck CK — continuing with CK monitoring is reasonable only for tolerable symptoms with a normal or minimally elevated CK, but weakness with CK greater than 10 times the upper limit of normal is severe statin myopathy that can progress to rhabdomyolysis, so the drug must be stopped rather than observed (underestimating severity)
Question 2CardiovascularEasy
A 65-year-old man with stable coronary artery disease (CAD) is taking maximally tolerated atorvastatin 80 mg daily for secondary prevention, with a treatment goal of LDL cholesterol below 70 mg/dL. His current LDL cholesterol is 84 mg/dL, and he asks about additional LDL-lowering therapy. Which of the following is the most appropriate next step in management?
ASwitch to pravastatin 80 mg
BAdd ezetimibe 10 mg daily
CAdd fenofibrate 145 mg daily
DAdd niacin 1000 mg daily
EAdd PCSK9 inhibitor therapy
Reveal answer & full explanation
Correct answer: B — Add ezetimibe 10 mg daily
ASwitch to pravastatin 80 mg
BAdd ezetimibe 10 mg daily✓
CAdd fenofibrate 145 mg daily
DAdd niacin 1000 mg daily
EAdd PCSK9 inhibitor therapy
Why Add ezetimibe 10 mg daily is correct
Secondary prevention LDL target is <70 mg/dL (ideally <55 mg/dL for very high risk)
After a maximally tolerated high-intensity statin (atorvastatin 80 mg or rosuvastatin 40 mg), the next step is a nonstatin add-on; reaching <70 mg/dL from 84 mg/dL needs only about a 17% further LDL reduction, so ezetimibe fits this small gap
Ezetimibe adds about a 20-25% LDL reduction to a statin and reduces cardiovascular (CV) events (IMPROVE-IT trial), per current ACC/AHA cholesterol guidance
Why the others are wrong
Add PCSK9 inhibitor therapy — A proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody (evolocumab, alirocumab) is also a Class I add-on under the 2026 ACC/AHA guideline (FOURIER, ODYSSEY trials), but its ~60% LDL drop is not needed for a 14 mg/dL gap; it is used for a larger gap or if LDL stays above goal on ezetimibe (overshoots-the-target)
Switch to pravastatin 80 mg — Pravastatin 80 mg is moderate-intensity and would represent a step down from high-intensity atorvastatin 80 mg (premature closure on 'just change the statin')
Add niacin 1000 mg daily — Niacin does not reduce CV events when added to statins (AIM-HIGH, HPS2-THRIVE trials) and is no longer recommended (outdated-practice trap)
Add fenofibrate 145 mg daily — a fibrate is a familiar second lipid drug to pair with a statin, but fenofibrate mainly lowers triglycerides rather than LDL, and adding it to a statin did not reduce CV events (ACCORD Lipid trial); it is used for severe hypertriglyceridemia, not to close an LDL gap (wrong-lipid-target trap)
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Hyperlipidemia outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
LDL particles infiltrate the arterial intima, where they undergo oxidation. Oxidized LDL is engulfed by macrophages → foam cells → fatty streaks → atherosclerotic plaque. Plaque progression narrows the lumen (stable angina) or destabilizes and ruptures (acute coronary syndrome). High TG ≥500 directly causes pancreatic ductal injury via free-fatty-acid release and chylomicronemia.
Clinical presentation
Symptoms
Almost always asymptomatic until ASCVD complication develops
Tendinous xanthomas, xanthelasma, corneal arcus (especially premature) — physical signs of severe / familial forms
Eruptive xanthomas on extensor surfaces — suggest TG >1000
Lipemic serum (milky appearance) when TG very high
Anorexia nervosa — Paradoxical elevation of cholesterol in severe restrictive eating; weight restoration normalizes
Diagnostic workup
Labs
Fasting lipid panel (10-12 h fast): total cholesterol, HDL, triglycerides, calculated LDL
Non-fasting acceptable for screening (per most current guidelines) — fasting required if TG >400 or for accurate LDL calculation
TSH (rule out hypothyroidism), A1c, BMP, LFTs (baseline before statin)
Lp(a) once in every adult (≥125 nmol/L or ≥50 mg/dL is a risk enhancer; ≥250 nmol/L about doubles risk); apoB can assess residual risk in metabolic syndrome, diabetes, high TG, or known ASCVD
Calculate 10-year ASCVD risk with PREVENT-ASCVD (ages 30-79 without ASCVD; replaced the Pooled Cohort Equations, which overestimated risk). Family history of premature ASCVD is a risk enhancer, not a calculator input. CAC score can refine borderline or intermediate risk
USPSTF 2022: statin for adults 40-75 with ≥1 CVD risk factor (dyslipidemia, diabetes, hypertension, smoking) and 10-yr risk ≥10% (grade B); selectively at 7.5-<10% (grade C)
Diagnostic algorithm
Risk category
Population
Statin and LDL-C goal
Very high-risk ASCVD
Recurrent ASCVD events, or one event plus multiple high-risk conditions (e.g., age ≥65, diabetes, CKD)
HIGH-intensity statin; LDL <55 (add ezetimibe, then PCSK9 antibody)
HIGH-intensity statin regardless of risk score; LDL <100, <70 with confirmed HeFH, added ASCVD risk factors or coronary calcium, <55 with clinical ASCVD
Diabetes, age 40-75
Also CKD stage ≥3 or HIV, age 40-75: treat regardless of score
At least MODERATE; HIGH (LDL <70) if ≥1 ASCVD risk factor
High (PREVENT ≥10%)
Primary prevention, ages 30-79
HIGH-intensity statin; LDL <70
Intermediate (PREVENT 5-<10%)
Primary prevention
MODERATE-intensity statin; LDL <100
Borderline (PREVENT 3-<5%)
Primary prevention
MODERATE-intensity reasonable after shared decision, favored by risk enhancers (family history, Lp(a) ≥125 nmol/L, inflammatory disease) or CAC >0; LDL <100
Low (PREVENT <3%)
Primary prevention
Lifestyle; statin reasonable if LDL 160-189
2026 ACC/AHA dyslipidemia guideline: statin intensity and LDL-C goal by risk category (PREVENT-ASCVD replaces the Pooled Cohort Equations). If the goal is not met on a maximally tolerated statin, add ezetimibe (or bempedoic acid), then a PCSK9 monoclonal antibody.
Statin intensity and LDL-C goal set by risk category (2026 ACC/AHA dyslipidemia guideline):
• Clinical ASCVD (MI, stable angina, stroke, TIA, PAD, revascularization) → HIGH-intensity statin; LDL goal <70, or <55 if very high risk (recurrent events, or one event plus multiple high-risk conditions such as age ≥65, diabetes, CKD)
• LDL ≥190 (severe hypercholesterolemia, suspect FH) → HIGH-intensity (maximally tolerated) statin regardless of calculated risk; LDL goal <100 (non-HDL <130), <70 (non-HDL <100) with clinically or genetically confirmed HeFH, added ASCVD risk factors or coronary calcium, <55 (non-HDL <85) with clinical ASCVD
• Diabetes age 40-75 → at least MODERATE-intensity; HIGH-intensity with LDL goal <70 if ≥1 ASCVD risk factor. Lipid-lowering therapy is also started at age 40-75 with CKD stage ≥3 or HIV regardless of risk score
• Primary prevention (PREVENT-ASCVD 10-yr risk, ages 30-79): high ≥10% → HIGH-intensity (goal LDL <70); intermediate 5-<10% → MODERATE-intensity (goal <100); borderline 3-<5% → MODERATE-intensity reasonable after shared decision-making, favored by risk enhancers or CAC >0 (goal <100); low <3% → lifestyle (statin reasonable if LDL 160-189)
TG-targeted therapy (TG ≥500, especially ≥1000, to prevent pancreatitis; TG 150-499 addressed only after the LDL goal is met):
• Fibrates (fenofibrate preferred over gemfibrozil for combination with statin); used to prevent pancreatitis, with no ASCVD event reduction on a statin (ACCORD-Lipid, PROMINENT)
• Icosapent ethyl (purified EPA) — TG 150-499 on a statin with ASCVD or diabetes plus risk factors reduces CV events (REDUCE-IT); mixed EPA/DHA omega-3s did not (STRENGTH)
• Niacin — rarely used due to side effects (flushing, hepatotoxicity, glycemia) and no CV event reduction when added to a statin (AIM-HIGH, HPS2-THRIVE)
Hepatotoxicity (mild ALT elevation common, hepatitis rare)
New-onset diabetes (small absolute risk increase, outweighed by CV benefit in most)
PANCE pearls
Check a baseline ALT before starting a statin (baseline CK only if at high risk for myopathy); routine surveillance LFTs are NO LONGER recommended unless symptomatic.
Statin myopathy: check CK if muscle symptoms; stop if CK >10× ULN or symptoms severe. Many patients tolerate a lower-intensity or different statin on re-challenge.
Drug interactions: statins metabolized by CYP3A4 (simvastatin, atorvastatin, lovastatin) interact with macrolides, azoles, amiodarone, grapefruit juice → ↑ rhabdo risk. Pravastatin and rosuvastatin avoid this pathway.
Lipoprotein(a) — genetically determined, not modified by lifestyle. Elevated Lp(a) is independent ASCVD risk; PCSK9 inhibitors lower it ~25%.
Familial hypercholesterolemia: cascade screen first-degree relatives. Children with an FH phenotype start a low-dose statin from age 8 when LDL stays ≥160 mg/dL despite 3-6 months of lifestyle therapy (2026 ACC/AHA), titrated upward; early treatment prevents premature ASCVD.
AHA/ACC 2018 — 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy et al., Circulation 2019)
FOURIER — Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (Sabatine et al., NEJM 2017)
ODYSSEY OUTCOMES — Alirocumab and Cardiovascular Outcomes after ACS (Schwartz et al., NEJM 2018)
REDUCE-IT — Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (Bhatt et al., NEJM 2019)
PREVENT equations — Development and Validation of the American Heart Association's PREVENT Equations (Khan SS et al., Circulation 2024;149:430-449)
ACC/AHA 2026 — 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (Blumenthal RS, Morris PB, et al., Circulation 2026;153(17):e1154-e1276; doi:10.1161/CIR.0000000000001423)
Practice Cardiovascular questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.